modifications and under flow conditions mimicking vessel wall hemodynamics. Considering the efficacy demonstrated here, CTLs show promise as the framework for a spatially-controlled drug delivery platform for future application in targeted vascular therapeutics. Objectives: Each year, >35,000 children are born in the United States with congenital heart defects. A vascular conduit is commonly used in the surgical repair of these defects. However, no currently available vascular conduit provides the potential for growth. For children with congenital heart diseases, this means having to undergo repeated operations due to the limitations of current vascular conduits. Pediatric patients with congenital cardiovascular defects would benefit greatly from an expandable conduit. To address this issue, PECA Labs has developed a novel expanded polytetrafluoroethylene vascular conduit with the capability of being radially expanded via balloon catheterization. We have shown previously that this novel expanded polytetrafluoroethylene material maintains its mechanical properties after expansion (Fig).
Objectives: Each year, >35,000 children are born in the United States with congenital heart defects. A vascular conduit is commonly used in the surgical repair of these defects. However, no currently available vascular conduit provides the potential for growth. For children with congenital heart diseases, this means having to undergo repeated operations due to the limitations of current vascular conduits. Pediatric patients with congenital cardiovascular defects would benefit greatly from an expandable conduit. To address this issue, PECA Labs has developed a novel expanded polytetrafluoroethylene vascular conduit with the capability of being radially expanded via balloon catheterization. We have shown previously that this novel expanded polytetrafluoroethylene material maintains its mechanical properties after expansion (Fig) .
Methods: In the described study, a systematic biocompatibility and chemical characterization was conducted to investigate the clinical viability of this novel expandable conduit material. The material is also undergoing proof-of-concept testing in a large-animal aortic replacement model. Pyrogenicity was tested in a rabbit model to determine the levels of chemical pyrogens in the material. New Zealand White rabbits were injected with the material extracts, and their temperature was monitored for 3 hours. Cytotoxicity was evaluated in vitro by culturing mouse fibroblast CCL-1 cells with the material and quantifying cell viability after 24 hours. Hemocompatibility was determined with a hemolysis test using rabbit blood. Whole rabbit blood was cultured with material extracts for 3 hours. Samples were then centrifuged to collect the supernatant to test for free hemoglobin. Additional testing, including irritation testing, the genotoxicity, and hemodynamics is currently ongoing. Implantation of the material in a 14-day rabbit implantation study is ongoing to determine the systemic toxicity of the material.
Results: The results from testing have thus far have illustrated the biocompatibility of this expandable conduit material. The expandable material is considered nonpyrogenic and meets the requirements of the Pyrogen Test, ISO 10993-11 guidelines. The material also meets the requirements to be nonhemolytic according to ASTM F756 guidelines and is not considered to have a cytotoxic potential based on ISO 10993-5 guidelines. Large-animal proof-of-concept testing and chemical characterization testing is currently underway, and results will be collected over the next 2 months.
Conclusions: Thus far, this study represents successful safety verification of this material and is a critical step toward clinical translation, providing hope for newborns and growing children with congenital heart disease. Objectives: Atherosclerotic plaque vulnerability and subsequent rupture are mediated by alterations in micro (mi)RNAs (miR) that promote inflammation and thinning of the fibrous cap, leading to carotid plaque rupture and an acute ischemic stroke. Changes in the expression of multiple microRNAs (miR) play an active role in the development of atherosclerotic plaque vulnerability. miR-27b and let7f possesses proangiogenic properties. miR-21 promotes while miR-23b inhibits vascular smooth muscle cell proliferation. As a fraction of these miRNAs are released from the plaque tissue into the circulation, they may provide a miRNA profile that functions as a biomarker panel to identify the vulnerable patient at risk of plaque rupture.
Methods: Carotid plaques and sera were obtained from patients undergoing carotid endarterectomy (CEA) for asymptomatic high-grade stenosis (n ¼ 24) and acutely symptomatic, urgent, carotid disease (n ¼ 17). Urgent CEA was defined as intervention during the index hospitalization, with a maximum time to intervention of 5 days from the acute neurologic event. miR-27b, miR-21, miR-23b, and miR-lem7f levels were measured in the shoulder region of carotid plaques and in the sera using droplet digital polymerase chain reaction. The Student nonpaired t-test was used to compare means between the two groups.
Results: Trends toward lower expression of let7f and miR-21 and elevated miR-23b and miR-27b were found in the serum of the urgent compared to the asymptomatic group. The ratio of the miRNA that increased to the miRNA that decreased was significantly elevated in the urgent group (2.4 6 0.7 vs 1.1 6 0.2; P < .05) and exhibited favorable characteristics as a biomarker indicative of carotid plaque rupture and stroke (C statistic ¼ 0.70 6 0.09, P < .05).
Conclusions: Carotid plaque rupture resulting in an acute ischemic event is associated with alterations in the profile of circulating miRNAs, and these may be useful as biomarkers of ischemic stroke. The serum ratio of increasing to decreasing miRNAs described here was able to differentiate between the urgent and asymptomatic groups. Our preliminary data suggest that the development of a score based on a panel of circulating miRNAs may allow for the diagnosis of patients experiencing plaque rupture and an acute ischemic stroke.
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Objectives: Myonephropathic metabolic syndrome is caused by ischemia-reperfusion injury to skeletal muscle, following revascularization of an acute arterial occlusion in an extremity. Although Fig. 
